ニューカッスル病ワクチンの世界市場規模：ワクチンタイプ別、生物種別、地域範囲別および予測

ニューカッスル病ワクチンの市場規模と予測

ニューカッスル病ワクチンの市場規模は、2024年には2億8,927万米ドルと評価され、2026～2032年にかけてCAGR 3.20%で成長し、2032年には3億7,216万米ドルに達すると予測されています。

ニューカッスル病は、鳥類パラミクソウイルス1型（APMV-1）によって引き起こされる鳥類の重篤なウイルス性疾患です。感染力が非常に強く、ニワトリやトルコを含む多くの家禽に感染し、特に雌鶏が感染しやすいです。このウイルスは糞口経路で感染します。つまり、汚染された糞、食品、飲料、病気の鳥と接触した器具などを鳥が摂取することで感染します。

米国国立医療図書館によれば、生後2～3週齢の市販トルコにニューカッスル病ウイルス（NDV）生ワクチンを噴霧接種した場合、赤血球凝集阻害検査で検出されるような高い血清抗体値や持続的な血清抗体値はあまり見られません。ワクチンを接種したトルコは、接種後2週目に眼鼻腔またはエアロゾル経路でチャレンジした場合、感染と臨床疾患に対して十分な抵抗性を示し、6週目にチャレンジした場合、臨床疾患に対して抵抗性を示したが、ワクチン接種後10週までに防御レベルは低下しました。

NDVが蔓延する環境で飼育されている開発期のトルコがNDV自然感染から完全に保護されるためには、2回以上のNDVスプレーワクチン接種が必要である可能性が示唆されました。

鳥類の重篤な呼吸困難や神経障害の発生率の増加が、ニューカッスル病ワクチン市場の大幅な拡大に寄与しています。この病気の発生拡大、食用家畜の需要拡大、この病気の治療法を生み出すための継続的な研究が、市場拡大の原動力になると予想されます。ニューカッスル病ワクチン市場は、人々の健康維持の利点に対する意識が高まり、消費者の間で質の高いヘルスケアサービスへの需要が高まるにつれて拡大しています。

ニューカッスル病ワクチン市場力学

世界のニューカッスル病ワクチン市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

疾患の流行：家禽集団におけるニューカッスル病（ND）の存在は、ニューカッスル病ワクチン産業の主要な促進要因です。NDは世界中の養鶏場に影響を与え続けているため、この病気の蔓延を防ぐための効果的なワクチンに対する需要は大きいです。

養鶏産業の成長：食肉や卵などの鶏肉製品に対する世界の需要の高まりに後押しされた養鶏産業の拡大は、ニューカッスル病ワクチン市場の牽引役となっています。鶏肉生産が増加し、新たな地域に広がるにつれ、包括的な予防接種プログラムの必要性がますます高まっています。

環境とバイオセキュリティへの懸念：バイオセキュリティと疾病発生が環境に与える影響に対する懸念の高まりが、予防接種のような予防手段の使用を促進しています。ニューカッスル病を回避するための積極的な対策は、環境を保護すると同時に、鶏の生産システムの長期的な存続を保証します。

疾病の発生：ニューカッスル病の発生は、特に家禽の生産地域において、予防接種の強化につながり、ニューカッスル病ワクチンの市場需要を生み出します。大発生は家禽生産者に大きな経済的損失をもたらす可能性があり、効果的なワクチン接種の取り組みの重要性を浮き彫りにしています。

主要課題

コスト面での制約：ニューカッスル病ワクチンは高コストであるため、特に資金力の乏しい小規模養鶏農業従事者では、導入の妨げとなります。経済的なワクチン製剤を開発し、費用対効果の高い予防接種方法を採用することは、特に低所得国において広く受け入れられ、病気をコントロールするために不可欠です。

バイオセキュリティ意識の向上：ニューカッスル病の発生がより一般的かつ大規模になるにつれ、農業従事者は自分たちの群れを守るためのバイオセキュリティ対策の重要性を認識しています。ワクチン接種はバイオセキュリティ対策の重要な要素であり、ニューカッスル病ワクチンの需要を押し上げています。

新型株の出現：ニューカッスル病ウイルスは常に変異しており、より攻撃的な新型株が出現しています。これらの新型株は現在のワクチンを効かなくする可能性があるため、新しく改良されたワクチンの開発が必要となります。これには長い時間とコストがかかります。

ワクチンへのアクセスは限られています。ニューカッスル病ワクチンなど、動物用ワクチンへのアクセスが限られている貧困国もあります。これは、不十分なインフラ、資金、認識など様々な問題によるものです。こうした国の農業従事者は、ニューカッスル病から家畜を守るための選択肢が少ないです。

主要動向

鶏肉製品に対する需要の高まり：鶏肉と卵に対する世界人口の食欲の拡大により、鶏肉生産が増加しています。このため、ヒナを殺し多大な経済的損失をもたらすニューカッスル病の発生から家禽を守るための予防接種の必要性が高まっています。

ニューカッスル病の経済的影響に関する知識の増加：養鶏業者は、ニューカッスル病がもたらす経済的損失について、より強く意識するようになっています。これには鳥類の死亡率、鶏卵生産量の減少、貿易制限などが含まれます。ワクチン接種は、これらの損失を防ぐための費用対効果の高い方法と考えられています。

ワクチン接種技術の進歩：より効果的で耐熱性の高いニューカッスル病ワクチンの研究開発が進められています。これは、ワクチンの保管や流通を容易にするため、冷蔵設備へのアクセスが限られている地域では特に重要です。

政府の法律と予防接種プログラム：多くの政府が、ニワトリのニューカッスル病に対する義務的なワクチン接種プログラムを採用しています。これは疾病の蔓延を抑制すると同時に、養鶏ビジネスを保護することにも役立っています。

目次

第1章 ニューカッスル病ワクチンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 ニューカッスル病ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 ニューカッスル病ワクチンの世界市場：ワクチンタイプ別

• 概要
• 生ワクチン
• 死菌ワクチン

第6章 ニューカッスル病ワクチンの世界市場：生物種別

• 概要
• ニワトリ
• アヒルとガチョウ
• その他

第7章 ニューカッスル病ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界のニューカッスル病ワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• Merck Animal Health
• GALVmed
• Elanco
• Boehringer Ingelheim
• QYH BIoTech
• Ceva Animal Health LLC
• Hester Biosciences Limited
• Zoetis, Inc.
• CAVAC

第10章 付録

• 関連調査

Newcastle Disease Vaccine Market Size And Forecast

Newcastle Disease Vaccine Market size was valued at USD 289.27 Million in 2024 and is projected to reach USD 372.16 Million by 2032, growing at a CAGR of 3.20% from 2026 to 2032.

Newcastle disease is a severe viral sickness in birds caused by avian paramyxovirus type 1 (APMV-1). It is very contagious and can spread too many domestic birds, including chickens and turkeys, with hens being especially vulnerable. The virus is spread by the fecal-oral route, which means that birds become infected after consuming contaminated droppings, food, drink, or equipment that has come into contact with sick birds.

According to National Library of Medicine, Commercial market turkeys spray-vaccinated at 2 to 3 weeks of age with live Newcastle disease virus (NDV) vaccine did not often generate high or persistent serum antibody levels as detected by the hemagglutination-inhibition test. Vaccinated turkeys demonstrated adequate resistance to infection and clinical disease when challenged by the oculonasal or aerosol route at 2 weeks post-vaccination, and they resisted clinical disease when challenged at 6 weeks, but the level of protection decreased by 10 weeks post-vaccination.

It is proposed that market turkeys raised in an NDV-enzootic environment may require two or more NDV spray vaccinations during their developing phase in order to be fully protected against natural NDV infection.

The increasing incidence of severe respiratory distress and nervous difficulties in birds contributes to the huge expansion of the Newcastle Disease Vaccine Market. Expanding outbreaks of the disease, expanding demand for livestock for food, and continuous research to produce a treatment for this disease are expected to drive market expansion. The Newcastle Disease Vaccine Market is thriving as people become more aware of the benefits of maintaining good health, resulting in a greater demand for high-quality healthcare services among consumers.

Newcastle Disease Vaccine Market Dynamics

The key market dynamics that are shaping the global Newcastle disease vaccine market include:

Key Market Drivers:

Disease Prevalence: The presence of Newcastle disease (ND) in poultry populations is a major driver of the Newcastle disease vaccine industry. As ND continues to affect poultry farms around the world, there is a great demand for effective vaccines to prevent the disease from spreading.

Growth of the Poultry Industry: The expansion of the poultry industry, fueled by rising global demand for chicken products such as meat and eggs, helps to drive the Newcastle disease vaccine market. As chicken production increases and spreads into new areas, the necessity for comprehensive immunization programs becomes increasingly pressing.

Environmental and Biosecurity Concerns: Growing concern about biosecurity and the environmental impact of disease outbreaks is driving the use of preventive measures like immunization. Proactive steps to avoid Newcastle disease can save the environment while also ensuring the long-term viability of chicken production systems.

Disease Outbreaks: Newcastle disease outbreaks, particularly in poultry-producing regions, lead to intensified immunization efforts and generate market demand for Newcastle disease vaccines. Outbreaks can cause large economic losses for poultry producers, highlighting the significance of effective vaccination efforts.

Key Challenges:

Cost Constraints: The high cost of Newcastle disease vaccines can deter adoption, especially among small-scale chicken breeders with limited financial resources. Developing economical vaccine formulations and adopting cost-effective immunization procedures is critical for ensuring widespread acceptance and disease control particularly in low-income nations.

Increased Biosecurity Awareness: As Newcastle disease outbreaks become more common and extensive, farmers recognize the significance of biosecurity measures to protect their flocks. Vaccination is a critical component of biosecurity measures, which is boosting the demand for Newcastle disease vaccine.

Emergence of New Strains: The Newcastle disease virus is constantly mutating, with new and more aggressive strains appearing. These novel strains may render current vaccines ineffective, prompting the creation of new and improved vaccines. This can be a long and costly process.

Limited Access to Vaccines: Some impoverished countries have limited access to veterinary vaccines, such as Newcastle disease vaccines. This is due to a variety of issues, including inadequate infrastructure, money, and awareness. Farmers in these nations have fewer options for protecting their animals from Newcastle disease.

Key Trends:

Rising Demand for Chicken Products: The global population's expanding appetite for poultry meat and eggs has resulted in increased poultry production. This increases the need for immunization to protect birds from Newcastle disease outbreaks, which may kill chicks and result in considerable economic losses.

Increasing Knowledge of Newcastle Disease's Economic Impact: Poultry growers are becoming more conscious of the financial losses caused by Newcastle disease. This includes avian mortality, reduced egg output, and trade restrictions. Vaccination is viewed as a cost-effective method of preventing these losses.

Advances in Vaccination Technology: Research and development are underway to build more effective and thermostable Newcastle disease vaccines. This is especially significant in areas with limited refrigeration access, as it facilitates vaccine storage and distribution.

Government Laws and Immunization Programs: Many governments have adopted mandatory vaccination programs against Newcastle disease in chicken. This helps to control disease spread while also protecting the poultry business.

Global Newcastle Disease Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Newcastle disease vaccine market:

North America:

The Newcastle disease vaccine market, owing to a robust chicken sector and high demand for poultry products, including meat and eggs. The region's chicken industry is well-established, but Newcastle disease poses ongoing challenges needing stringent preventive measures such as immunization. This need emphasizes the importance of Newcastle disease vaccines in protecting the region's poultry stock and assuring the continuation of its thriving poultry market.

Furthermore, North America's unwavering dedication to sustainable agriculture techniques and animal welfare encourages the use of Newcastle disease vaccines. Prioritizing poultry health and well-being demonstrates the region's commitment to sustaining high food safety and animal care standards, which resonates positively with both consumers and industry stakeholders.

North America's dominant market position not only represents its enormous contribution to the global Newcastle disease vaccine market, but also demonstrates its unwavering commitment to safeguarding the poultry industry's viability and resilience in the face of evolving disease threats.

Asia Pacific:

The Asia-Pacific region is expected to lead the Newcastle disease vaccine market, as it is home to some of the world's top poultry producers, including China, India, and Indonesia. Here, rising demand for poultry products, fueled by population growth and changing dietary habits, drives the need to protect poultry flocks from Newcastle disease outbreaks. As a result, there is a significant increase in demand for vaccines, emphasizing the importance of preventive measures in supporting the region's thriving poultry sector.

Furthermore, the Asia-Pacific area is experiencing tremendous development in the poultry business, as well as increased knowledge of biosecurity regulations. This double momentum not only strengthens the Newcastle disease vaccine market but also demonstrates the region's proactive approach to disease prevention in chicken production. These factors firmly position Asia-Pacific as a key catalyst for Newcastle disease vaccine market growth, demonstrating its critical role in maintaining the global poultry industry's resilience in the face of changing challenges.

Europe:

The European market is primed to emerge as a serious competitor, boosted by proactive government programs that assist research and development efforts, particularly in the field of Newcastle disease vaccines. With significant investments in improving veterinary science and tight regulatory frameworks, the region creates an atmosphere conducive to innovation in animal health solutions.

Furthermore, Europe's significant advancements in animal husbandry procedures strengthen its position in the Newcastle disease vaccine market. By embracing innovative techniques and technology aimed at improving animal welfare and disease prevention, the region demonstrates its commitment to upholding high animal health and food safety standards. This combination of government funding, scientific excellence, and modern husbandry techniques puts Europe as a major player set to make great advances in the international Newcastle disease vaccine market.

Global Newcastle Disease Vaccine Market: Segmentation Analysis

The Global Newcastle Disease Vaccine Market is segmented on the basis of Vaccine Type, Species, And Geography.

Newcastle Disease Vaccine Market, By Vaccine Type

• Live Attenuated
• Inactivated
• Thermostable

Based on Vaccine Type, the market is divided into Live Attenuated, Inactivated and Thermostable. The Live Attenuated Vaccines (LAV) segment dominated the market in 2022 and is expected to have the highest compound annual growth rate (CAGR) over the forecast period. LAVs have remained popular among poultry breeders due to their effectiveness, low cost, and potential to provide long-term immunity. These vaccines have demonstrated efficacy against many strains of Newcastle disease viruses and provide broad-spectrum protection.

Newcastle Disease Vaccine Market, By Species

• Chicken
• Duck
• Goose

Based on Species, the Newcastle disease vaccine market is segmented Chicken, Duck and Goose. The chicken sector grabbed the biggest market share and is expected to retain a significant compound annual growth rate (CAGR) over the projection period. Newcastle Disease Virus (NDV) is a major threat to the poultry industry, causing significant economic losses. As a result, the demand for Newcastle Disease Vaccines remains high among chicken farmers, making this segment the most profitable in the market.

Newcastle Disease Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of regional analysis, the Global Newcastle Disease Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share of Newcastle disease vaccine followed by Europe. Growing demand for effective emergency care and increasing adoption of mobile surgery centers are anticipated to drive the industry during the forecast period.

Key Players

The "Global Newcastle disease vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merial, QYH Biotech, CEVA, Yebio, Ringpu (Tianjin) Bio-Pharmacy Co. Ltd,Bayer AG, Hipra, Anicon Labor GmbH, Chengdu Tech-bank Biological Products Co. Ltd., Ringpu Bio-Technology Co. Ltd., MSD Animal Health, Nisseiken Co., Harbin Veterinary Research Institute, Merck Animal Health, ChengDu Tecbond, DHN, Zoetis, Elanco (Lohmann), CAVAC, Vaksindo, FATRO. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Newcastle Disease Vaccine Market Recent Developments
• In June 2022, Ceva Sante bought Canadian firm Artemis Technologies, Inc. to extend its oral rabies vaccine line. Ceva's North American presence will be expanded as a result of this transaction.
• In April 2020, The Indian Institute of Technology Guwahati and Hester Biosciences cooperated to create a new coronavirus vaccine (COVID-19). The vaccine is based on a recombinant avian paramyxovirus vector platform.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NEWCASTLE DISEASE VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NEWCASTLE DISEASE VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY VACCINE TYPE

• 5.1 Overview
• 5.2 Live vaccines
• 5.3 Killed vaccines

6 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY SPECIES

• 6.1 Overview
• 6.2 Chicken
• 6.3 Duck and goose
• 6.4 Others

7 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL NEWCASTLE DISEASE VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Merck Animal Health
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 GALVmed
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Elanco
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Boehringer Ingelheim
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 QYH Biotech
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Ceva Animal Health LLC
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Hester Biosciences Limited
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Zoetis, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 CAVAC
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 Appendix

• 10.1 Related Research